HC Wainwright Has Bearish Estimate for CAPR FY2026 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – HC Wainwright lowered their FY2026 EPS estimates for Capricor Therapeutics in a report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($2.76) per share for the year, down from their previous forecast of ($2.75). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.71) per share.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29).

Several other equities analysts also recently commented on CAPR. Wall Street Zen downgraded shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Tuesday, July 28th. JonesTrading raised Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday. Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Finally, B. Riley Financial raised Capricor Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $5.00 to $21.00 in a research report on Monday, September 14th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $29.77.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $10.24 on Friday. Capricor Therapeutics has a 12-month low of $2.96 and a 12-month high of $40.37. The company’s fifty day simple moving average is $8.10 and its two-hundred day simple moving average is $19.92.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Walleye Capital LLC bought a new position in Capricor Therapeutics in the 1st quarter worth $5,397,000. Bank of America Corp DE boosted its stake in shares of Capricor Therapeutics by 672.0% during the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares in the last quarter. Montanova Capital LLC boosted its stake in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in shares of Capricor Therapeutics during the 1st quarter valued at about $3,463,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Capricor Therapeutics during the second quarter valued at about $3,895,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.